Ignite Creation Date:
2024-05-06 @ 1:13 PM
Last Modification Date:
2024-10-26 @ 1:10 PM
Study NCT ID:
NCT03964233
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-07-09
First Post:
2019-05-24
Brief Title:
A Study in Patients With Different Types of Advanced Cancer Solid Tumors to Test Different Doses of BI 907828 Brigimadlin in Combination With BI 754091 Ezabenlimab and BI 754111 or BI 907828 Brigimadlin in Combination With BI 754091 Ezabenlimab
Sponsor:
Organization:
Boehringer Ingelheim
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
119
Enrollment Type:
ACTUAL
Design Primary Purpose:
Design Masking:
Phases:
| Name |
|---|
| PHASE1 |
Observational Models:
Time Perspective List:
Who Masked List: